Suppr超能文献

资源有限环境下的心力衰竭管理:来自印度的专家意见

Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India.

作者信息

Jain Peeyush, Guha Santanu, Kumar Soumitra, Sawhney J P S, Sharma Kamal, Sureshkumar K P, Mehta Ashwani, Dhediya Rajnish, Gaurav Kumar, Mittal Rajan, Kotak Bhavesh

机构信息

Fortis Escorts Heart Institute, New Delhi, India.

Medical College, Kolkata, India.

出版信息

Cardiol Ther. 2024 Jun;13(2):243-266. doi: 10.1007/s40119-024-00367-4. Epub 2024 Apr 30.

Abstract

Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption, clinical inertia, and delayed diagnosis. Despite international recommendations promoting the use of guideline-directed medical therapy for heart failure management, personalized approaches are essential in settings with resource constraints. In India, crucial treatments like angiotensin II receptor blocker neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors are not fully utilized despite their established safety and efficacy. To address this issue, an expert consensus involving 150 specialists, including cardiologists, nephrologists, and endocrinologists, was convened. They deliberated on patient profiles, monitoring, and adverse side effects and provided tailored recommendations for guideline-directed medical therapy in heart failure management. Stressing the significance of early initiation of guideline-directed medical therapy in patients with heart failure, especially with sodium-glucose co-transporter 2 inhibitors, the consensus also explored innovative therapies like vericiguat. To improve heart failure outcomes in resource-limited settings, the experts proposed several measures, including enhanced patient education, cardiac rehabilitation, improved drug access, and reforms in healthcare policies.

摘要

心力衰竭是一项全球性的健康挑战,影响着数百万人,获得指南指导的药物治疗往往受到限制。这种限制通常归因于药物可及性、采用缓慢、临床惰性和诊断延迟等因素。尽管国际上推荐使用指南指导的药物治疗来管理心力衰竭,但在资源有限的环境中,个性化方法至关重要。在印度,血管紧张素 II 受体脑啡肽酶抑制剂和钠-葡萄糖协同转运蛋白 2 抑制剂等关键治疗方法尽管已证实其安全性和有效性,但并未得到充分利用。为解决这一问题,召集了包括心脏病专家、肾病专家和内分泌专家在内的 150 名专家达成了专家共识。他们审议了患者情况、监测和不良副作用,并为心力衰竭管理中的指南指导药物治疗提供了量身定制的建议。该共识强调了在心力衰竭患者中尽早开始指南指导药物治疗的重要性,特别是对于钠-葡萄糖协同转运蛋白 2 抑制剂,并探讨了如维立西呱等创新疗法。为改善资源有限环境中的心力衰竭治疗效果,专家们提出了多项措施,包括加强患者教育、心脏康复、改善药物可及性以及医疗政策改革。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8478/11093928/104605ca634a/40119_2024_367_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验